The European healthcare private equity (PE) landscape is undergoing a structural reallocation of capital. Private equity sponsors, growth equity funds and institutional investors are shifting capital away from early-stage, speculative diagnostic tools and high-risk Software as a Medical Device (SaMD) platforms toward mission-critical operational workflow software. Historically, diagnostic artificial intelligence and novel MedTech tools commanded premium valuations based on t